The company's research focuses on developing first-in-class Resolvin therapies that can regulate the body's normal inflammatory response without compromising immune function. Their Resolvins are potent agonists of inflammation resolution and tissue repair, making them a unique class of endogenous molecules that regulate immune homeostasis. Thetis aims to use Resolvins to treat cancer and autoimmune diseases, providing patients with a new and effective treatment option.